Open an account

Indaptus Therapeutics

INDP · NASDAQ

$2.96+$0.23 (+8.42%)TodayMarket closed ·
Prev close $2.73

About INDP

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 5 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

Employees
5
Headquarters
New York City, New York
Listed
Sep 7, 2012
Sector
Health Care
Industry
Biotechnology
Website
indaptusrx.com

INDP key statistics

Market cap
454.60M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
555.97K
Volume
218.75K
Open price
$2.75
High today
$2.97
Low today
$2.70
52 Week high
$5.96
52 Week low
$0.92

Indaptus Therapeutics (INDP) at a glance

Indaptus Therapeutics (INDP) last traded at $2.96, with a market cap of 454.60M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.70 and $2.97. The current price is 9.6% above the day's low and 0.3% below its high.

Volume so far is 218.75K shares, below the average of 555.97K shares a day.

Over the past year Indaptus Therapeutics has ranged from $0.92 to $5.96, and now sits 40% of the way up that range.

Indaptus Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q4 FY25 it reported -$4.51 per share against an estimate of -$4.45.

INDP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 19.9% on average.

  1. Q1 FY24: reported -$12.60 per share against an estimate of -$16.28
  2. Q2 FY24: reported -$13.16 per share against an estimate of -$15.42
  3. Q3 FY24: reported -$8.96 per share against an estimate of -$13.42
  4. Q4 FY24: reported -$10.64 per share against an estimate of -$12.57
  5. Q1 FY25: reported -$8.96 per share against an estimate of -$5.14
  6. Q2 FY25: reported -$9.09 per share against an estimate of -$9.42
  7. Q3 FY25: reported -$2.98 per share against an estimate of -$4.25
  8. Q4 FY25: reported -$4.51 per share against an estimate of -$4.45

INDP news

  • Avi Kapoor

    Crude Oil Down 3%; Kroger Shares Gain After Upbeat Q2 Earnings

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Market-Moving News for December 24th

  • Shivdeep Dhaliwal

    Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today

Similar companies

Companies in the same industry as Indaptus Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.